Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day period.
The device, Dexcom G7 15 Day, is a wearable continuous glucose monitor, or CGM. It helps people track their blood sugar in real time, improving the management of diabetes. The first generation of G7 was designed to be worn for up to 10 days, with a 12-hour grace period to swap it out at the end. Now, the FDA will allow the CGM for 15 days for people age 18 and older with the same 12-hour grace period.
Jake Leach, the company's chief operating officer, says the Dexcom G7 15 Day marks "another major innovation for Dexcom."
"By listening to the needs of our users, we're proud to offer the longest lasting wearable and most accurate CGM, giving people the knowledge to better control their diabetes with our best-in-class technology," he said in a statement.
Dexcom stock rose 0.7%, paring back from a much steeper gain in premarket and early action. That followed a 10.1% pop on Wednesday after President Donald Trump delayed his tariffs plan by 90 days for some 75-plus trading partners.
15.5-Day Wear Time
Abbott Laboratories' FreeStyle Libre CGM can be worn for up to 15 days, while Medtronic's CGMs can be worn for up to a week.
Dexcom notes the G7 15 Day is highly accurate with an overall MARD, or mean absolute relative difference, of 8%. The MARD calculates the difference between CGM readings and reference blood glucose levels, with a lower MARD signaling better accuracy. Abbott's Libre 3 touts a 7.9% MARD.
While Dexcom stock rose, Abbott shares fell 2% to 124.47. Medtronic stock dipped 3.2% to 82.54.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
